CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services CADTH Common Drug Review Reports vedolizumab
Back to Programs and Services

CADTH Common Drug Review

vedolizumab

Last Updated: July 27, 2020
Result type: Reports
Project Number: SR0647-000
Product Line: Common Drug Review

Generic Name: vedolizumab

Brand Name: Entyvio

Manufacturer: Takeda Canada Inc.

Indications: Crohn’s disease

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNF antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

Submission Type: New

Project Status: Received

Companion Diagnostics: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openMay 05, 2020
Call for patient input closedJune 24, 2020
Clarification:

- Patient input submission received from Crohn’s and Colitis Canada and Gastrointestinal Society

Submission receivedJuly 23, 2020
Submission accepted-